Kathy Nguyen
Family · Concord, CANPI 1700459583
Payments from drug & device makers
Across 139 payments — averaging $25.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$657
- AbbVie$632
- Sumitomo Pharma America, Inc.$373
- Urogen Pharma, Inc.$160
- Antares Pharma, Inc.$157
- Myriad Genetic Laboratories, Inc.$155
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,26394%
- Education$2196%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 20 | $657 |
| AbbVie | 32 | $632 |
| Sumitomo Pharma America, Inc. | 12 | $373 |
| Urogen Pharma, Inc. | 7 | $160 |
| Antares Pharma, Inc. | 9 | $157 |
| Myriad Genetic Laboratories, Inc. | 7 | $155 |
| Olympus America Inc. | 2 | $146 |
| Immunitybio, Inc. | 4 | $126 |
| Merck | 5 | $126 |
| Pfizer | 5 | $110 |
| UCB, Inc. | 3 | $88 |
| Angiodynamics, Inc. | 3 | $83 |
| Procept Biorobotics Corporation | 3 | $71 |
| Verity Pharmaceuticals Inc. | 3 | $69 |
| Bayer | 2 | $61 |
| Boston Scientific | 3 | $56 |
| Urovant Sciences Inc | 2 | $45 |
| Ambu Inc. | 2 | $41 |
| Coloplast | 2 | $40 |
| Tolmar, Inc. | 1 | $37 |
| Pharmaand GmbH | 1 | $37 |
| AstraZeneca | 1 | $35 |
| ABC Home Medical Supply, Inc. | 2 | $33 |
| Smith+Nephew | 1 | $24 |
| Calyxo, Inc. | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Halozyme Inc | 1 | $18 |
| Fennec Pharmaceuticals, Inc. | 1 | $16 |
| Profound Medical Corp. | 1 | $14 |
| 180 Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEMTESA$125
- BOTOX$125
- RYBREVANT$122
- CARVYKTI$122
- iTIND System$109
How this compares
$3,482 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 131 | $120,762 |
| MyrbetriqMirabegron | 44 | $46,048 |
| Estradiol | 178 | $12,638 |
| Tamsulosin Hcl | 452 | $8,310 |
| Finasteride | 151 | $2,532 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,835 |
| Solifenacin Succinate | 24 | $1,651 |
| Dutasteride | 26 | $1,274 |
| Cefpodoxime Proxetil | 23 | $1,129 |
| NitrofurantoinNitrofurantoin Macrocrystal | 21 | $862 |
| Testosterone | 12 | $786 |
| Trimethoprim | 11 | $643 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 59 | $581 |
| Testosterone Cypionate | 16 | $550 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 22 | $474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $373 | $120,762131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in Concord
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.